



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

BC HIV Treatment Program

Monthly Report
August 2025



FOREWORD

The British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) is a provincial treatment and research program, with the mandate to improve the health of people living with HIV (“PLWH”), and those at elevated risk of acquiring HIV in British Columbia (BC), by advancing and promoting programs for treatment and prevention of HIV, and related conditions, guided by Treatment as Prevention® (TasP®) principles. Funded by the BC’s Ministry of Health, through the province’s PharmaCare Program, the BC-CfE’s Drug Treatment Programs provide medications for HIV treatment, prevention, and select related conditions, at no charge, to medically eligible BC residents living with HIV, or at elevated risk of HIV acquisition. The provision of these medications are based on guidelines developed by the BC-CfE’s Committee for Drug Evaluation and Therapy (CDET) and program consideration.

A key component of the BC-CfE’s mandate is to monitor and evaluate its HIV Treatment Program, reporting on a regular basis and providing essential information to BC’s health authorities, treating clinicians, and the community at large. This HIV Treatment Program Report provides an overview of the use of antiretroviral medications in BC for the treatment of HIV, common drug combinations, key monitoring parameters, and distribution of program participants throughout the province.

Figures and graphs in this document are best viewed in colour.

Please note that any comments or queries regarding this report should be forwarded to info@bccfe.ca.

BC Centre for Excellence in HIV/AIDS Drug Treatment Programs

St. Paul’s Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through BC’s PharmaCare and Ministry of Health.

DISCLAIMER: All information presented in this report is generated from a secure, live database maintained by the BC-CfE. Privacy and confidentiality are matters which are taken very seriously and strict rules and procedures are applied to ensure that the information stored is secure.

Figures and tables provided in this report represent the best estimates at the time the document was generated, and may be subject to change. Please be advised that the information in this document is provided in good faith and is derived from sources understood to be accurate and up-to-date at the report’s date of publication.

© 2026 BC Centre for Excellence in HIV/AIDS



TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.3 Distribution of Participants in HIV Treatment Program by Regimen Category
- 1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
- 1.7 Number of Participants on Protease Inhibitors by INGREDIENT
- 1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
- 1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
- 1.11 Number of Participants on Integrase Inhibitors by INGREDIENT
- 1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT
- 1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (graph)
- 1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals (table)
- 1.16 Percent Distribution of Active Participants by CD4 Count
- 1.17 Distribution of Active Participants by CD4 Count
- 1.18 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (graph)
- 1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment (table)
- 1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (graph)
- 1.21 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program (table)
- 1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (graph)
- 1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment (table)
- 1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance (graph)
- 1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance (table)

2. List of Tables

- 2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of January 2025
- 2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment
- 2.3 BC-CfE HIV Treatment Program Enrolment

3. Distribution of HIV Treatment Program Active Participants

- 3.1 Provincial Health Authorities
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

TABLE OF CONTENTS (continued)

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants by Age & Sex at Birth
- 4.2 Distribution of Participants by Program Duration
- 4.3 Distribution of Antiretroviral Treatment Prescribers

FRASER HEALTH

- 4.4 Distribution of Participants by Age & Sex at Birth
- 4.5 Distribution of Participants by Program Duration
- 4.6 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER COASTAL

- 4.7 Distribution of Participants by Age & Sex at Birth
- 4.8 Distribution of Participants by Program Duration
- 4.9 Distribution of Antiretroviral Treatment Prescribers

VANCOUVER ISLAND

- 4.10 Distribution of Participants by Age & Sex at Birth
- 4.11 Distribution of Participants by Program Duration
- 4.12 Distribution of Antiretroviral Treatment Prescribers

NORTHERN HEALTH


- 4.13 Distribution of Participants by Age & Sex at Birth
- 4.14 Distribution of Participants by Program Duration
- 4.15 Distribution of Antiretroviral Treatment Prescribers

INDIGENOUS PARTICIPANTS

- 4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth



1.1 Distribution of Participants on Antiretroviral Treatment in British Columbia by Health Authority August 2025
N = 7762




Health Authority	Male	Female	All
FRASER	1652	509	2161
VANCOUVER ISLAND	884	177	1061
VANCOUVER COASTAL	3214	446	3660
INTERIOR	489	122	611
NORTHERN	176	85	261
	6415	1339	7754
Unknown/not stated			8
Total			7762

On antiretroviral treatment is defined as being on treatment in the current month
Unknown/not stated is defined as being on treatment in the current month, and city of residence is unknown
Male & Female refer to Sex assigned at birth



1.2 Distribution of Participants in HIV Treatment Program by Regimen Category
August 2020 - August 2025



1.3 Distribution of Participants in HIV Treatment Program by Regimen Category

MON-YYYY	Total	INSTI		Boosted PI		NNRTI		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
SEP-2023	7609	4793	63.0	639	8.4	616	8.1	879	11.6	617	8.1	65	0.9
OCT-2023	7610	4808	63.2	615	8.1	611	8.0	897	11.8	618	8.1	61	0.8
NOV-2023	7612	4799	63.0	611	8.0	599	7.9	918	12.1	624	8.2	61	0.8
DEC-2023	7603	4808	63.2	593	7.8	596	7.8	936	12.3	614	8.1	56	0.7
JAN-2024	7642	4856	63.5	583	7.6	585	7.7	952	12.5	609	8.0	57	0.7
FEB-2024	7647	4861	63.6	564	7.4	586	7.7	971	12.7	609	8.0	56	0.7
MAR-2024	7636	4846	63.5	543	7.1	580	7.6	991	13.0	618	8.1	58	0.8
APR-2024	7670	4884	63.7	538	7.0	570	7.4	1000	13.0	621	8.1	57	0.7
MAY-2024	7687	4902	63.8	536	7.0	566	7.4	1023	13.3	607	7.9	53	0.7
JUN-2024	7687	4910	63.9	526	6.8	556	7.2	1033	13.4	606	7.9	56	0.7
JUL-2024	7718	4938	64.0	520	6.7	541	7.0	1060	13.7	605	7.8	54	0.7
AUG-2024	7709	4933	64.0	505	6.6	537	7.0	1081	14.0	602	7.8	51	0.7
SEP-2024	7697	4911	63.8	484	6.3	530	6.9	1124	14.6	595	7.7	53	0.7
OCT-2024	7725	4938	63.9	467	6.0	512	6.6	1167	15.1	593	7.7	48	0.6
NOV-2024	7703	4946	64.2	464	6.0	490	6.4	1176	15.3	581	7.5	46	0.6
DEC-2024	7720	4949	64.1	456	5.9	479	6.2	1199	15.5	588	7.6	49	0.6
JAN-2025	7739	4959	64.1	437	5.6	478	6.2	1234	15.9	586	7.6	45	0.6
FEB-2025	7696	4929	64.0	419	5.4	460	6.0	1264	16.4	577	7.5	47	0.6
MAR-2025	7689	4921	64.0	408	5.3	453	5.9	1291	16.8	572	7.4	44	0.6
APR-2025	7719	4947	64.1	394	5.1	432	5.6	1320	17.1	584	7.6	42	0.5
MAY-2025	7705	4911	63.7	386	5.0	423	5.5	1369	17.8	573	7.4	43	0.6
JUN-2025	7713	4893	63.4	371	4.8	417	5.4	1427	18.5	565	7.3	40	0.5
JUL-2025	7772	4940	63.6	359	4.6	411	5.3	1457	18.7	564	7.3	41	0.5
AUG-2025	7762	4921	63.4	346	4.5	407	5.2	1478	19.0	565	7.3	45	0.6

n is number of participants on the specified regimen class in the specified month


% is ratio of **n** and total number of participants on antiretroviral treatment in the specified month

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.4 Distribution of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT
August 2020 - August 2025




1.5 Number of Participants on Nucleos(t)ide Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	abacavir		emtricitabine		lamivudine		tenofovir <TAF>		tenofovir <TDF>		zidovudine	
		n	%	n	%	n	%	n	%	n	%	n	%
SEP-2023	7478	1910	25.5	4578	61.2	2902	38.8	3746	50.1	954	12.8	13	0.2
OCT-2023	7474	1895	25.4	4573	61.2	2904	38.9	3766	50.4	935	12.5	14	0.2
NOV-2023	7474	1866	25.0	4585	61.4	2891	38.7	3783	50.6	918	12.3	15	0.2
DEC-2023	7464	1831	24.5	4595	61.6	2874	38.5	3820	51.2	895	12.0	13	0.2
JAN-2024	7502	1831	24.4	4633	61.8	2881	38.4	3866	51.5	890	11.9	13	0.2
FEB-2024	7504	1795	23.9	4641	61.9	2868	38.2	3896	51.9	864	11.5	13	0.2
MAR-2024	7493	1759	23.5	4656	62.1	2845	38.0	3927	52.4	844	11.3	13	0.2
APR-2024	7525	1742	23.2	4690	62.3	2844	37.8	3968	52.7	843	11.2	13	0.2
MAY-2024	7544	1706	22.6	4734	62.8	2822	37.4	4018	53.3	832	11.0	12	0.2
JUN-2024	7544	1691	22.4	4738	62.8	2817	37.3	4047	53.7	801	10.6	13	0.2
JUL-2024	7570	1667	22.0	4763	62.9	2812	37.2	4077	53.9	800	10.6	13	0.2
AUG-2024	7563	1633	21.6	4771	63.1	2796	37.0	4097	54.2	782	10.3	13	0.2
SEP-2024	7551	1600	21.2	4769	63.2	2797	37.0	4113	54.5	768	10.2	13	0.2
OCT-2024	7577	1556	20.5	4810	63.5	2789	36.8	4170	55.0	754	10.0	13	0.2
NOV-2024	7555	1499	19.8	4821	63.8	2744	36.3	4193	55.5	739	9.8	11	0.2
DEC-2024	7572	1481	19.6	4835	63.9	2756	36.4	4223	55.8	734	9.7	11	0.2
JAN-2025	7591	1431	18.9	4873	64.2	2740	36.1	4273	56.3	721	9.5	10	0.1
FEB-2025	7547	1370	18.2	4860	64.4	2698	35.8	4280	56.7	701	9.3	8	0.1
MAR-2025	7537	1335	17.7	4869	64.6	2680	35.6	4312	57.2	684	9.1	8	0.1
APR-2025	7557	1304	17.3	4909	65.0	2664	35.3	4374	57.9	655	8.7	6	0.1
MAY-2025	7537	1242	16.5	4894	64.9	2654	35.2	4373	58.0	630	8.4	7	0.1
JUN-2025	7540	1196	15.9	4910	65.1	2647	35.1	4406	58.4	620	8.2	7	0.1
JUL-2025	7593	1137	15.0	4981	65.6	2629	34.6	4482	59.0	615	8.1	7	0.1
AUG-2025	7579	1076	14.2	4993	65.9	2596	34.3	4512	59.5	594	7.8	7	0.1

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.6 Distribution of Participants on Protease Inhibitors by INGREDIENT
August 2020 - August 2025




1.7 Number of Participants on Protease Inhibitors by INGREDIENT

MON-YYYY	Total Participants	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
		n	%	n	%	n	%	n	%	n	%
SEP-2023	1214	271	22.3	909	74.9	35	2.9	0	0.0	0	0.00
OCT-2023	1198	273	22.8	893	74.5	35	2.9	0	0.0	0	0.00
NOV-2023	1184	260	22.0	890	75.2	35	3.0	0	0.0	0	0.00
DEC-2023	1156	248	21.5	876	75.8	33	2.9	0	0.0	0	0.00
JAN-2024	1138	241	21.2	866	76.1	33	2.9	0	0.0	0	0.00
FEB-2024	1111	229	20.6	852	76.7	31	2.8	0	0.0	0	0.00
MAR-2024	1094	225	20.6	840	76.8	30	2.7	0	0.0	0	0.00
APR-2024	1088	224	20.6	835	76.8	31	2.9	0	0.0	0	0.00
MAY-2024	1081	221	20.4	828	76.6	33	3.1	0	0.0	0	0.00
JUN-2024	1059	214	20.2	813	76.8	33	3.1	0	0.0	0	0.00
JUL-2024	1052	216	20.5	805	76.5	33	3.1	0	0.0	0	0.00
AUG-2024	1021	208	20.4	784	76.8	31	3.0	0	0.0	0	0.00
SEP-2024	1001	203	20.3	772	77.1	27	2.7	0	0.0	0	0.00
OCT-2024	977	197	20.2	754	77.2	27	2.8	0	0.0	0	0.00
NOV-2024	957	190	19.9	742	77.5	28	2.9	0	0.0	0	0.00
DEC-2024	947	184	19.4	738	77.9	26	2.8	0	0.0	0	0.00
JAN-2025	922	177	19.2	726	78.7	23	2.5	0	0.0	0	0.00
FEB-2025	891	168	18.9	700	78.6	24	2.7	0	0.0	0	0.00
MAR-2025	875	167	19.1	686	78.4	24	2.7	0	0.0	0	0.00
APR-2025	860	153	17.8	684	79.5	24	2.8	0	0.0	0	0.00
MAY-2025	840	151	18.0	666	79.3	24	2.9	0	0.0	0	0.00
JUN-2025	823	150	18.2	652	79.2	23	2.8	0	0.0	0	0.00
JUL-2025	806	146	18.1	639	79.3	23	2.9	0	0.0	0	0.00
AUG-2025	788	142	18.0	624	79.2	23	2.9	0	0.0	0	0.00

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Ritonavir - greater than 400 mg total daily dose

1.8 Distribution of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT
August 2020 - August 2025




1.9 Number of Participants on Non-Nucleoside Analogue Reverse Transcriptase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	doravirine n %	efavirenz n %	etravirine n %	nevirapine n %	rilpivirine n %
SEP-2023	938	236 25.2	218 23.2	88 9.4	220 23.5	177 18.9
OCT-2023	932	238 25.5	216 23.2	89 9.6	220 23.6	173 18.6
NOV-2023	928	242 26.1	209 22.5	88 9.5	219 23.6	173 18.6
DEC-2023	929	250 26.9	205 22.1	87 9.4	213 22.9	176 19.0
JAN-2024	921	250 27.1	200 21.7	83 9.0	208 22.6	181 19.7
FEB-2024	919	257 28.0	192 20.9	82 8.9	207 22.5	182 19.8
MAR-2024	914	260 28.5	190 20.8	80 8.8	205 22.4	181 19.8
APR-2024	915	261 28.5	190 20.8	82 9.0	203 22.2	180 19.7
MAY-2024	906	262 28.9	186 20.5	80 8.8	205 22.6	175 19.3
JUN-2024	893	262 29.3	182 20.4	79 8.9	198 22.2	172 19.3
JUL-2024	890	270 30.3	176 19.8	78 8.8	194 21.8	172 19.3
AUG-2024	879	272 30.9	174 19.8	78 8.9	187 21.3	171 19.5
SEP-2024	886	275 31.0	172 19.4	76 8.6	185 20.9	179 20.2
OCT-2024	871	283 32.5	168 19.3	72 8.3	177 20.3	175 20.1
NOV-2024	850	287 33.8	162 19.1	70 8.2	159 18.7	173 20.4
DEC-2024	844	303 35.9	156 18.5	71 8.4	149 17.7	167 19.8
JAN-2025	844	309 36.6	157 18.6	67 7.9	143 16.9	172 20.4
FEB-2025	834	306 36.7	156 18.7	64 7.7	136 16.3	173 20.7
MAR-2025	823	311 37.8	147 17.9	62 7.5	132 16.0	173 21.0
APR-2025	818	317 38.8	137 16.8	61 7.5	128 15.7	177 21.6
MAY-2025	809	313 38.7	129 16.0	60 7.4	126 15.6	181 22.4
JUN-2025	812	315 38.8	127 15.6	60 7.4	122 15.0	190 23.4
JUL-2025	809	322 39.8	124 15.3	56 6.9	113 14.0	194 24.0
AUG-2025	805	329 40.9	117 14.5	57 7.1	109 13.5	198 24.6

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class

1.10 Distribution of Participants on Integrase Inhibitors by INGREDIENT
August 2020 - August 2025






1.11 Number of Participants on Integrase Inhibitors by INGREDIENT

MON-YYYY	Total Participants	bictegravir n %	cabotegravir n %	dolutegravir n %	elvitegravir n %	raltegravir n %
SEP-2023	6263	3289 52.5	8 0.1	2500 39.9	238 3.8	249 4.0
OCT-2023	6294	3298 52.4	7 0.1	2523 40.1	241 3.8	248 3.9
NOV-2023	6311	3327 52.7	9 0.1	2518 39.9	233 3.7	244 3.9
DEC-2023	6330	3365 53.2	13 0.2	2506 39.6	226 3.6	237 3.7
JAN-2024	6389	3418 53.5	16 0.3	2520 39.4	224 3.5	234 3.7
FEB-2024	6417	3453 53.8	15 0.2	2516 39.2	219 3.4	231 3.6
MAR-2024	6435	3498 54.4	17 0.3	2500 38.9	220 3.4	225 3.5
APR-2024	6483	3545 54.7	17 0.3	2497 38.5	216 3.3	225 3.5
MAY-2024	6511	3586 55.1	19 0.3	2488 38.2	213 3.3	222 3.4
JUN-2024	6528	3614 55.4	21 0.3	2488 38.1	207 3.2	218 3.3
JUL-2024	6584	3650 55.4	25 0.4	2500 38.0	212 3.2	213 3.2
AUG-2024	6593	3683 55.9	26 0.4	2487 37.7	204 3.1	207 3.1
SEP-2024	6610	3700 56.0	32 0.5	2495 37.8	200 3.0	205 3.1
OCT-2024	6680	3757 56.2	34 0.5	2508 37.5	198 3.0	199 3.0
NOV-2024	6681	3791 56.7	33 0.5	2487 37.2	191 2.9	193 2.9
DEC-2024	6720	3819 56.8	33 0.5	2521 37.5	185 2.8	187 2.8
JAN-2025	6762	3866 57.2	36 0.5	2525 37.3	185 2.7	179 2.7
FEB-2025	6754	3883 57.5	41 0.6	2495 36.9	183 2.7	176 2.6
MAR-2025	6767	3913 57.8	48 0.7	2481 36.7	181 2.7	175 2.6
APR-2025	6834	3985 58.3	49 0.7	2488 36.4	176 2.6	167 2.4
MAY-2025	6840	3987 58.3	57 0.8	2478 36.2	174 2.5	165 2.4
JUN-2025	6868	4021 58.6	67 1.0	2483 36.2	170 2.5	162 2.4
JUL-2025	6952	4102 59.0	75 1.1	2478 35.6	168 2.4	159 2.3
AUG-2025	6955	4133 59.4	81 1.2	2453 35.3	162 2.3	159 2.3

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
% is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class



1.12 Distribution of Participants on Other Antiretroviral Drug Classes by INGREDIENT
August 2020 - August 2025






1.13 Number of Participants on Other Antiretroviral Drug Classes by INGREDIENT

MON-YYYY	Total Participants	fostemsavir		maraviroc		lenacapavir	
		n	%	n	%	n	%
SEP-2023	20	2	10.0	18	90.0	0	0.0
OCT-2023	20	2	10.0	18	90.0	1	5.0
NOV-2023	19	1	5.3	17	89.5	1	5.3
DEC-2023	19	2	10.5	16	84.2	1	5.3
JAN-2024	21	2	9.5	18	85.7	1	4.8
FEB-2024	21	2	9.5	18	85.7	1	4.8
MAR-2024	21	3	14.3	17	81.0	2	9.5
APR-2024	22	2	9.1	18	81.8	2	9.1
MAY-2024	19	2	10.5	15	79.0	2	10.5
JUN-2024	21	2	9.5	17	81.0	2	9.5
JUL-2024	21	2	9.5	17	81.0	2	9.5
AUG-2024	21	2	9.5	17	81.0	2	9.5
SEP-2024	20	2	10.0	16	80.0	2	10.0
OCT-2024	20	2	10.0	15	75.0	3	15.0
NOV-2024	20	2	10.0	16	80.0	2	10.0
DEC-2024	20	2	10.0	16	80.0	2	10.0
JAN-2025	20	2	10.0	16	80.0	2	10.0
FEB-2025	19	2	10.5	15	79.0	2	10.5
MAR-2025	19	2	10.5	15	79.0	2	10.5
APR-2025	19	2	10.5	15	79.0	2	10.5
MAY-2025	17	2	11.8	14	82.4	1	5.9
JUN-2025	19	2	10.5	15	79.0	2	10.5
JUL-2025	22	2	9.1	16	72.7	4	18.2
AUG-2025	24	2	8.3	16	66.7	6	25.0

n is defined as number of participants on antiretroviral treatment which contains the INGREDIENT;
 % is calculated as ratio of "n" and number of participants whose treatment is of the given antiretroviral drug class
 Both lenacapavir and fostemsavir are currently not on BC-CfE Formulary



1.14 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals
August 2020 - August 2025




1.15 Distribution of Participants on Antiretroviral Treatment by Number of Antiretrovirals

MON-YYYY	Total Participants	1 drug		2 drugs		3 drugs		4 drugs		5 or more drugs	
		n	%	n	%	n	%	n	%	n	%
SEP-2023	7609	2	0.0	879	11.6	6250	82.1	432	5.7	46	0.6
OCT-2023	7610	2	0.0	897	11.8	6237	82.0	433	5.7	41	0.5
NOV-2023	7612	2	0.0	918	12.1	6210	81.6	441	5.8	41	0.5
DEC-2023	7603	2	0.0	936	12.3	6191	81.4	434	5.7	40	0.5
JAN-2024	7642	2	0.0	952	12.5	6214	81.3	432	5.7	42	0.6
FEB-2024	7647	3	0.0	971	12.7	6198	81.1	436	5.7	39	0.5
MAR-2024	7636	2	0.0	991	13.0	6159	80.7	440	5.8	44	0.6
APR-2024	7670	2	0.0	1001	13.1	6184	80.6	437	5.7	46	0.6
MAY-2024	7687	2	0.0	1024	13.3	6188	80.5	434	5.7	39	0.5
JUN-2024	7687	1	0.0	1034	13.5	6181	80.4	429	5.6	42	0.6
JUL-2024	7718	2	0.0	1061	13.8	6184	80.1	434	5.6	37	0.5
AUG-2024	7709	2	0.0	1082	14.0	6155	79.8	431	5.6	39	0.5
SEP-2024	7697	2	0.0	1125	14.6	6101	79.3	426	5.5	43	0.6
OCT-2024	7725	1	0.0	1169	15.1	6087	78.8	427	5.5	41	0.5
NOV-2024	7703	1	0.0	1177	15.3	6069	78.8	417	5.4	39	0.5
DEC-2024	7720	2	0.0	1200	15.5	6054	78.4	424	5.5	40	0.5
JAN-2025	7739	2	0.0	1235	16.0	6047	78.1	416	5.4	39	0.5
FEB-2025	7696	2	0.0	1265	16.4	5977	77.7	414	5.4	38	0.5
MAR-2025	7689	4	0.1	1292	16.8	5942	77.3	414	5.4	37	0.5
APR-2025	7719	3	0.0	1321	17.1	5939	76.9	419	5.4	37	0.5
MAY-2025	7705	4	0.1	1370	17.8	5882	76.3	410	5.3	39	0.5
JUN-2025	7713	4	0.1	1428	18.5	5845	75.8	396	5.1	40	0.5
JUL-2025	7772	2	0.0	1460	18.8	5874	75.6	399	5.1	37	0.5
AUG-2025	7762	5	0.1	1482	19.1	5839	75.2	396	5.1	40	0.5

n is the number of individual drugs in antiretroviral treatment regimen (excluding low dose ritonavir and cobicistat used for pharmacokinetic boosting)



1.16 Percent Distribution of Active Participants by CD4 Count
August 2020 - August 2025





1.17 Distribution of Active Participants by CD4 Count

Month	# of Pts with CD4: Unreported	# of Pts with CD4: < 200	# of Pts with CD4: 200 - 349	# of Pts with CD4: 350 - 500	# of Pts with CD4: > 500
SEP-2023	1303	243	547	951	3744
OCT-2023	1351	242	543	943	3727
NOV-2023	1386	237	542	937	3689
DEC-2023	1427	237	530	917	3703
JAN-2024	1464	238	529	916	3679
FEB-2024	1503	242	503	911	3673
MAR-2024	1531	255	498	924	3649
APR-2024	1573	253	486	944	3627
MAY-2024	1608	248	486	923	3661
JUN-2024	1643	247	493	886	3680
JUL-2024	1705	248	493	912	3682
AUG-2024	1747	251	491	910	3660
SEP-2024	1766	241	489	935	3639
OCT-2024	1802	243	499	948	3624
NOV-2024	1834	234	505	917	3652
DEC-2024	1862	232	508	928	3658
JAN-2025	1886	233	509	939	3650
FEB-2025	1908	223	511	930	3640
MAR-2025	1932	225	508	934	3620
APR-2025	1968	230	500	902	3667
MAY-2025	1991	229	493	875	3653
JUN-2025	2030	223	477	899	3654
JUL-2025	2060	215	510	883	3695
AUG-2025	2125	217	503	877	3713

CD4 value (cells/ μ L) as per the most recent test within the past 12 months

CD4 Unreported: CD4 not tested or reported within the past 12 months

Active Participants are participants with antiretroviral treatment in the month based on dispensing record




1.19 Initial Regimen Composition for Antiretroviral Treatment Naïve Participants Starting Treatment

MON-YYYY	Total	INSTI 2 N(t)RTIs		Boosted PI 2 N(t)RTIs		NNRTI 2 N(t)RTIs		2 drugs from 2 classes		≥3 drugs from ≥3 classes		Other	
		n	%	n	%	n	%	n	%	n	%	n	%
SEP-2023	5	5	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2023	10	9	90.0	0	0.0	0	0.0	1	10.0	0	0.0	0	0.0
NOV-2023	9	7	77.8	0	0.0	0	0.0	1	11.1	1	11.1	0	0.0
DEC-2023	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
JAN-2024	11	9	81.8	0	0.0	0	0.0	0	0.0	2	18.2	0	0.0
FEB-2024	11	11	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2024	13	12	92.3	0	0.0	0	0.0	0	0.0	1	7.7	0	0.0
APR-2024	20	18	90.0	0	0.0	0	0.0	0	0.0	2	10.0	0	0.0
MAY-2024	16	16	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2024	23	22	95.7	0	0.0	0	0.0	0	0.0	1	4.3	0	0.0
JUL-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
SEP-2024	7	7	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
OCT-2024	15	15	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
NOV-2024	9	8	88.9	0	0.0	1	11.1	0	0.0	0	0.0	0	0.0
DEC-2024	10	10	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JAN-2025	14	14	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
FEB-2025	9	9	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
APR-2025	12	12	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
MAY-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUN-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
JUL-2025	8	8	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
AUG-2025	17	17	100.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor, **N(t)RTI:** Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor
n is number of participants on the specified regimen category in the specified month
% is ratio of n and total number of participants initiating antiretroviral treatment in the specified month



1.20 Pre-entry CD4 for Antiretroviral Treatment Naïve Participants in the HIV Treatment Program
August 2020 - August 2025




1.21 Pre-entry CD4 for Antiretroviral Treatment Naive Participants in the HIV Treatment Program

MON-YYYY	# of First Starts	# of Pts with CD4: Unreported		# of Pts with CD4: < 200		# of Pts with CD4: 200 - 349		# of Pts with CD4: 350 - 500		# of Pts with CD4: > 500	
		n	%	n	%	n	%	n	%	n	%
SEP-2023	5	0	0.0	2	40.0	0	0.0	0	0.0	3	60.0
OCT-2023	10	1	10.0	1	10.0	3	30.0	2	20.0	3	30.0
NOV-2023	9	1	11.1	2	22.2	0	0.0	2	22.2	4	44.4
DEC-2023	13	1	7.7	1	7.7	3	23.1	0	0.0	8	61.5
JAN-2024	11	1	9.1	4	36.4	2	18.2	1	9.1	3	27.3
FEB-2024	11	1	9.1	3	27.3	4	36.4	2	18.2	1	9.1
MAR-2024	13	2	15.4	5	38.5	1	7.7	1	7.7	4	30.8
APR-2024	20	0	0.0	4	20.0	6	30.0	1	5.0	9	45.0
MAY-2024	16	1	6.3	5	31.3	3	18.8	1	6.3	6	37.5
JUN-2024	23	0	0.0	2	8.7	10	43.5	4	17.4	7	30.4
JUL-2024	10	1	10.0	1	10.0	3	30.0	3	30.0	2	20.0
AUG-2024	15	0	0.0	5	33.3	4	26.7	3	20.0	3	20.0
SEP-2024	7	0	0.0	1	14.3	4	57.1	1	14.3	1	14.3
OCT-2024	15	0	0.0	6	40.0	3	20.0	3	20.0	3	20.0
NOV-2024	9	0	0.0	3	33.3	3	33.3	2	22.2	1	11.1
DEC-2024	10	0	0.0	4	40.0	2	20.0	2	20.0	2	20.0
JAN-2025	14	0	0.0	6	42.9	2	14.3	5	35.7	1	7.1
FEB-2025	9	0	0.0	2	22.2	1	11.1	3	33.3	3	33.3
MAR-2025	12	1	8.3	5	41.7	2	16.7	2	16.7	2	16.7
APR-2025	12	1	8.3	3	25.0	2	16.7	2	16.7	4	33.3
MAY-2025	17	1	5.9	6	35.3	3	17.7	5	29.4	2	11.8
JUN-2025	8	0	0.0	2	25.0	3	37.5	2	25.0	1	12.5
JUL-2025	8	2	25.0	0	0.0	2	25.0	2	25.0	2	25.0
AUG-2025	17	2	11.8	3	17.7	1	5.9	6	35.3	5	29.4

First Starts defined as participants starting antiretroviral treatment in the specified month for the first time (antiretroviral treatment naive)
Pre-entry CD4 (cells/ μ L) is defined as most recent CD4 test before antiretroviral treatment start

1.22 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment
August 2020 - August 2025



1.23 Antiretroviral Resistance by Drug Class Among Participants on Antiretroviral Treatment

MON-YYYY	On Antiretroviral (ARV) Treatment	Ever Tested	NNRTI		N(t)RTI		PI		INSTI	
			n	%	n	%	n	%	n	%
SEP-2023	7579	6406	1304	20.4	1645	25.7	557	8.7	104	1.6
OCT-2023	7579	6394	1307	20.4	1648	25.8	552	8.6	99	1.6
NOV-2023	7578	6388	1307	20.5	1644	25.7	558	8.7	101	1.6
DEC-2023	7574	6374	1306	20.5	1634	25.6	553	8.7	100	1.6
JAN-2024	7613	6399	1306	20.4	1645	25.7	549	8.6	102	1.6
FEB-2024	7620	6409	1301	20.3	1647	25.7	562	8.8	102	1.6
MAR-2024	7616	6393	1294	20.2	1638	25.6	555	8.7	105	1.6
APR-2024	7647	6411	1299	20.3	1637	25.5	563	8.8	102	1.6
MAY-2024	7666	6419	1301	20.3	1637	25.5	566	8.8	103	1.6
JUN-2024	7678	6419	1306	20.4	1626	25.3	560	8.7	101	1.6
JUL-2024	7697	6425	1315	20.5	1636	25.5	557	8.7	107	1.7
AUG-2024	7686	6410	1304	20.3	1620	25.3	547	8.5	105	1.6
SEP-2024	7674	6391	1299	20.3	1622	25.4	553	8.7	102	1.6
OCT-2024	7702	6408	1285	20.1	1618	25.3	555	8.7	99	1.5
NOV-2024	7674	6374	1279	20.1	1614	25.3	544	8.5	97	1.5
DEC-2024	7693	6373	1279	20.1	1601	25.1	541	8.5	101	1.6
JAN-2025	7712	6374	1272	20.0	1588	24.9	529	8.3	105	1.7
FEB-2025	7673	6328	1268	20.0	1575	24.9	530	8.4	106	1.7
MAR-2025	7668	6327	1259	19.9	1561	24.7	531	8.4	108	1.7
APR-2025	7701	6344	1263	19.9	1568	24.7	524	8.3	104	1.6
MAY-2025	7676	6322	1265	20.0	1561	24.7	529	8.4	104	1.7
JUN-2025	7692	6321	1262	20.0	1554	24.6	521	8.2	104	1.7
JUL-2025	7749	6359	1265	19.9	1559	24.5	520	8.2	105	1.7
AUG-2025	7739	6343	1264	19.9	1563	24.6	522	8.2	107	1.7

On Antiretroviral (ARV) Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever Tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the month of interest.

n: number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug in the corresponding drug class in BC. Participants may have resistance to none or 1 or more drug class(es).

% is calculated as ratio of "n" and number of participants on ARV treatment who were ever tested for ARV resistance with drug resistance to ≥ 1 drug the corresponding drug class in BC.

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.


HIVdb scores ≥ 15 are classified as "resistant".

INSTI: Integrase Inhibitor, **PI:** Protease Inhibitor, **NNRTI:** Non-Nucleoside Analogue Reverse Transcriptase Inhibitor,

N(t)RTI: Nucleos(t)ide Analogue Reverse Transcriptase Inhibitor



1.24 Active Participants by number of Antiretroviral Drug Classes with Resistance
August 2020 - August 2025



1.25 Active Participants by number of Antiretroviral Drug Classes with Resistance

MON-YYYY	On Antiretroviral Treatment	Ever Tested	0-Class (Wild Type)		1-Class		2-Class		3 or more Class	
			n	%	n	%	n	%	n	%
SEP-2023	7579	6406	4098	64.0	1281	20.0	755	11.8	272	4.3
OCT-2023	7579	6394	4086	63.9	1282	20.1	758	11.9	268	4.2
NOV-2023	7578	6388	4076	63.8	1288	20.2	754	11.8	270	4.2
DEC-2023	7574	6374	4070	63.9	1287	20.2	749	11.8	268	4.2
JAN-2024	7613	6399	4087	63.9	1293	20.2	751	11.7	268	4.2
FEB-2024	7620	6409	4098	63.9	1285	20.1	755	11.8	271	4.2
MAR-2024	7616	6393	4096	64.1	1277	20.0	749	11.7	271	4.2
APR-2024	7647	6411	4103	64.0	1292	20.2	743	11.6	273	4.3
MAY-2024	7666	6419	4107	64.0	1292	20.1	749	11.7	271	4.2
JUN-2024	7678	6419	4117	64.1	1286	20.0	743	11.6	273	4.3
JUL-2024	7697	6425	4110	64.0	1294	20.1	746	11.6	275	4.3
AUG-2024	7686	6410	4115	64.2	1288	20.1	737	11.5	270	4.2
SEP-2024	7674	6391	4098	64.1	1286	20.1	735	11.5	272	4.3
OCT-2024	7702	6408	4120	64.3	1288	20.1	734	11.5	266	4.2
NOV-2024	7674	6374	4098	64.3	1282	20.1	732	11.5	262	4.1
DEC-2024	7693	6373	4104	64.4	1277	20.0	733	11.5	259	4.1
JAN-2025	7712	6374	4115	64.6	1277	20.0	731	11.5	251	3.9
FEB-2025	7673	6328	4078	64.4	1274	20.1	724	11.4	252	4.0
MAR-2025	7668	6327	4086	64.6	1276	20.2	715	11.3	250	4.0
APR-2025	7701	6344	4104	64.7	1273	20.1	718	11.3	249	3.9
MAY-2025	7676	6322	4082	64.6	1273	20.1	718	11.4	249	3.9
JUN-2025	7692	6321	4091	64.7	1268	20.1	716	11.3	246	3.9
JUL-2025	7749	6359	4121	64.8	1276	20.1	716	11.3	246	3.9
AUG-2025	7739	6343	4103	64.7	1274	20.1	719	11.3	247	3.9

Number of Antiretroviral (ARV) Drug Classes with Resistance considers N(t)RTIs, NNRTIs, PIs, and INSTIs only, based on cumulative resistance tests performed in BC (until the specified month) for participants ever tested (see definition below).

Resistance interpretations are performed using the Stanford University HIV Drug Resistance Database Algorithm (HIVdb) version 9.8.

HIVdb scores ≥ 15 are classified as "resistant".

On Antiretroviral Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program.

Ever tested: those on ARV treatment, with at least one ARV resistance test on record in BC, up until the specified month.





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of August 2025

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
Pre-1993	31	45	178	170	8	34	(30, 39)	89	550	(400, 690)	162	<40	(<40, <40)
1993	30	118	119	105	14	34	(29, 40)	71	630	(430, 805)	111	<40	(<40, <40)
1994	29	68	68	58	10	35	(30, 37)	44	655	(473, 843)	63	<40	(<40, <40)
1995	28	124	125	106	19	34	(29, 39)	73	610	(450, 780)	115	<40	(<40, <40)
1996	27	316	318	275	43	35	(30, 39)	184	620	(430, 813)	282	<40	(<40, <40)
1997	24	260	266	243	23	34	(30, 39)	157	620	(400, 860)	235	<40	(<40, <40)
1998	24	182	191	159	32	34	(30, 40)	127	590	(420, 780)	172	<40	(<40, <40)
1999	24	164	165	128	37	36	(30, 42)	113	590	(370, 830)	153	<40	(<40, <40)
2000	24	119	122	99	23	38	(33, 44)	77	680	(430, 800)	110	<40	(<40, <40)
2001	23	120	122	97	25	37	(31, 44)	74	580	(390, 758)	114	<40	(<40, <40)
2002	22	116	126	107	19	40	(31, 46)	77	570	(440, 740)	117	<40	(<40, <40)
2003	22	139	149	128	21	39	(34, 45)	97	590	(410, 830)	127	<40	(<40, <40)
2004	21	141	163	127	36	40	(35, 44)	106	640	(405, 840)	152	<40	(<40, <40)
2005	20	181	198	157	41	41	(34, 47)	139	652	(475, 875)	185	<40	(<40, <40)
2006	19	178	196	158	38	42	(33, 48)	136	610	(449, 818)	181	<40	(<40, <40)
2007	18	233	251	217	34	41	(35, 46)	170	660	(443, 860)	223	<40	(<40, <40)
2008	17	275	309	252	57	42	(34, 48)	226	680	(500, 900)	274	<40	(<40, <40)
2009	16	297	328	271	57	41	(34, 47)	218	660	(480, 920)	290	<40	(<40, <40)
2010	15	256	298	236	62	40	(32, 45)	210	670	(500, 860)	266	<40	(<40, <40)
2011	14	318	361	296	65	41	(33, 48)	230	720	(500, 899)	313	<40	(<40, <40)
2012	13	275	312	253	59	40	(32, 49)	199	740	(535, 965)	286	<40	(<40, <40)
2013	12	250	296	238	58	41	(32, 49)	191	700	(490, 915)	259	<40	(<40, <40)
2014	11	222	286	246	40	40	(31, 50)	182	760	(560, 988)	247	<40	(<40, <40)
2015	10	195	278	238	40	41	(31, 51)	183	700	(500, 915)	252	<40	(<40, <40)
2016	9	177	252	208	44	38	(32, 49)	173	680	(480, 900)	222	<40	(<40, <40)
2017	8	154	222	191	31	36	(28, 45)	153	690	(530, 940)	205	<40	(<40, <40)
2018	7	136	209	166	43	39	(31, 48)	136	755	(556, 983)	173	<40	(<40, <40)
2019	6	129	245	203	42	38	(29, 48)	188	730	(515, 900)	218	<40	(<40, <40)
2020	5	101	198	147	51	37	(31, 49)	155	700	(480, 940)	174	<40	(<40, <40)

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
 CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.1 Active participants by Year of Program Initiation (1987 - 2025) - as of August 2025 (cont.)

DTP Start Year	Duration (years) Median	First Starts	All	Male	Female	Age		(n)	CD4 (cells/μL)		(n)	pVL (copies/mL)	
						Median	(Q1, Q3)		Median	(Q1, Q3)		Median	(Q1, Q3)
2021	4	114	205	172	33	37	(30, 46)	176	650	(455, 855)	143	<40	(<40, <40)
2022	3	110	271	221	50	38	(31, 47)	251	680	(540, 910)	205	<40	(<40, <40)
2023	2	114	316	259	57	35	(30, 45)	290	645	(468, 840)	244	<40	(<40, <40)
2024	1	139	347	281	66	36	(29, 45)	321	610	(430, 810)	298	<40	(<40, <40)
2025	0	93	249	191	58	36	(30, 46)	245	580	(370, 754)	239	<40	(<40, 41)
Total:		5859	7739	6403	1336								

Duration defined as cumulative years on antiretroviral treatment, excluding periods of treatment interruption
CD4 and pVL tests defined as most recent test done in the last 12 months and last 6 months, respectively





2.2 HIV Viral Load (copies/mL) and CD4 (cells/ μ L) for Participants on Antiretroviral Treatment

MON-YYYY	Total Participants	Median # of Treatment days	(n)	CD4 (cells/ μ L)		(n)	pVL (copies/mL)	
				Median	(Q1, Q3)		Median	(Q1, Q3)
SEP-2023	7609	796	5485	650	(450, 860)	6893	<40	(<40, <40)
OCT-2023	7610	803	5455	640	(450, 860)	6812	<40	(<40, <40)
NOV-2023	7612	795	5405	640	(450, 860)	6841	<40	(<40, <40)
DEC-2023	7603	798	5387	650	(460, 860)	6829	<40	(<40, <40)
JAN-2024	7642	792	5362	640	(460, 860)	6815	<40	(<40, <40)
FEB-2024	7647	781	5329	650	(460, 870)	6865	<40	(<40, <40)
MAR-2024	7636	790	5326	640	(450, 870)	6872	<40	(<40, <40)
APR-2024	7670	786	5310	640	(450, 870)	6843	<40	(<40, <40)
MAY-2024	7687	787	5318	650	(460, 880)	6897	<40	(<40, <40)
JUN-2024	7687	784	5306	650	(460, 870)	6922	<40	(<40, <40)
JUL-2024	7718	786	5335	650	(460, 870)	7010	<40	(<40, <40)
AUG-2024	7709	782	5312	650	(460, 873)	6938	<40	(<40, <40)
SEP-2024	7697	791	5304	650	(460, 870)	6905	<40	(<40, <40)
OCT-2024	7725	787	5314	650	(460, 870)	6899	<40	(<40, <40)
NOV-2024	7703	793	5308	650	(460, 880)	6876	<40	(<40, <40)
DEC-2024	7720	796	5326	650	(460, 880)	6914	<40	(<40, <40)
JAN-2025	7739	792	5331	650	(450, 880)	6883	<40	(<40, <40)
FEB-2025	7696	800	5304	650	(460, 880)	6871	<40	(<40, <40)
MAR-2025	7689	792	5287	650	(450, 875)	6813	<40	(<40, <40)
APR-2025	7719	779	5299	660	(460, 880)	6891	<40	(<40, <40)
MAY-2025	7705	787	5250	660	(460, 880)	6861	<40	(<40, <40)
JUN-2025	7713	785	5253	660	(460, 880)	6835	<40	(<40, <40)
JUL-2025	7772	773	5303	651	(460, 870)	6914	<40	(<40, <40)
AUG-2025	7762	780	5310	660	(460, 860)	6943	<40	(<40, <40)

Active participant defined as being on antiretroviral treatment in the specified month

Treatment days defined as number of consecutive days on antiretroviral treatment (most recent uninterrupted period)

CD4 and pVL tests defined as tests done in the specified month





2.3 BC-CfE HIV Treatment Program Enrolment

MON-YYYY	On ARV Treatment	Off ARV Treatment	Deceased	ARV Treatment naïve starts	ARV Treatment experienced starts	Newly interrupted ARV Treatment	Net Change
SEP-2023	7579	715	14	5	179	163	2
OCT-2023	7579	725	18	10	170	160	0
NOV-2023	7578	732	18	9	182	171	-1
DEC-2023	7574	741	14	13	169	169	-4
JAN-2024	7613	699	16	11	204	159	39
FEB-2024	7620	696	17	11	184	165	7
MAR-2024	7616	710	12	13	183	185	-4
APR-2024	7647	693	17	20	197	168	31
MAY-2024	7666	692	12	16	191	173	19
JUN-2024	7678	707	5	23	173	177	12
JUL-2024	7697	696	15	10	185	159	19
AUG-2024	7686	711	13	15	164	168	-11
SEP-2024	7674	717	9	7	182	186	-12
OCT-2024	7702	710	8	15	200	172	28
NOV-2024	7674	747	14	9	181	199	-28
DEC-2024	7693	744	15	10	194	170	19
JAN-2025	7712	717	14	14	196	170	19
FEB-2025	7673	760	10	9	166	201	-39
MAR-2025	7668	760	12	12	175	177	-5
APR-2025	7701	737	9	12	192	157	33
MAY-2025	7676	758	18	17	167	188	-25
JUN-2025	7692	737	12	8	175	150	16
JUL-2025	7749	697	8	8	203	141	57
AUG-2025	7739	716	11	17	148	163	-10

ARV: antiretroviral

On ARV Treatment: based on dispensing data, participants with a record of ARV medication in the specified month and not deceased or moved out of program

Off ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month and not deceased or moved out of program

Deceased: in the specified month, and on ARV treatment in the previous month

ARV Treatment naïve starts: participants starting ARV treatment in the specified month for the first time


ARV Treatment experienced starts: participants with history of ARV treatment, but first dispensing in the BC HIV Treatment Program in the specified month

Newly Interrupted ARV Treatment: based on dispensing data, participants with no record of ARV medication in the specified month, but had a record of ARV medication in the previous month, and not deceased or moved out of program, and had contact with the program in the past 5 years.

Net Change: the difference between ARV treatment starts (naïve and experienced) and ARV treatment stops (Deceased, moved out of program, or newly interrupted ARV treatment)




3.1 Distribution of HIV Treatment Program Active Participants August 2025






3.2 Distribution of HIV Treatment Program Active Participants August 2025

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV Treatment Program Active Participants August 2025

FRASER HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE




3.4 Distribution of HIV Treatment Program Active Participants August 2025

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE




*** Please refer to VIHA (432 and 434) on the next page






3.5 Distribution of HIV Treatment Program Active Participants August 2025

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV Treatment Program Active Participants August 2025

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICE DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE



4.1 Distribution of Participants by Age & Sex at Birth INTERIOR Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	0 - 29	0	0	0	0	N/A	*	*
	30 - 49	16	13	0	15	740	*	*
	50 - 64	12	11	0	12	730	*	*
	65+	7	7	0	6	595	*	*
	Total HSDA:	35	31	0	33	740	28	<40
KOOTENAY BOUNDARY	0 - 29	5	5	0	5	880	*	*
	30 - 49	14	12	0	12	735	*	*
	50 - 64	21	18	0	18	575	*	*
	65+	18	18	0	13	740	*	*
	Total HSDA:	58	53	0	48	725	44	<40
OKANAGAN	0 - 29	14	13	0	14	710	12	<40
	30 - 49	129	117	0	117	700	103	<40
	50 - 64	154	139	0	139	670	127	<40
	65+	88	83	0	81	570	76	<40
	Total HSDA:	385	352	0	351	660	318	<40
THOMPSON/CARIBOO/SHUSWAP	0 - 29	14	12	0	11	680	10	<40
	30 - 49	56	48	0	48	725	44	<40
	50 - 64	87	80	0	68	680	66	<40
	65+	36	35	0	30	715	33	<40
	Total HSDA:	193	175	0	157	700	153	<40
Total HA:		671	611	0	589	680	543	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	33	30	0	30	755	25	<40
	30 - 49	215	190	0	192	705	172	<40
	50 - 64	274	248	0	237	670	217	<40
	65+	149	143	0	130	605	129	<40
Total HA:		671	611	0	589	680	543	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	536	489	0	463	670	435	<40
Female	135	122	0	126	700	108	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	611	56	680	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)



4.2 Distribution of Participants by Program Duration INTERIOR Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
EAST KOOTENAY	10 years or more	17	14	0	16	710	11	<40
	5 years or more	11	11	0	8	815	10	<40
	<5 years	7	6	0	9	750	7	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	35	31	0	33	740	28	<40
KOOTENAY BOUNDARY	10 years or more	43	40	0	35	710	*	*
	5 years or more	7	6	0	5	780	*	*
	<5 years	8	7	0	8	690	*	*
	Never on ART	0	0	0	0	N/A	*	*
	Total HSDA:	58	53	0	48	725	44	<40
OKANAGAN	10 years or more	245	223	0	222	670	199	<40
	5 years or more	58	53	0	53	670	46	<40
	<5 years	82	76	0	76	610	73	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	385	352	0	351	660	318	<40
THOMPSON/CARIBOO/SHUSWAP	10 years or more	121	110	0	*	*	*	*
	5 years or more	25	21	0	*	*	*	*
	<5 years	47	44	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
	Total HSDA:	193	175	0	157	700	153	<40
Total HA:		671	611	0	589	680	543	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	426	387	0	*	*	*	*
	5 years or more	101	91	0	*	*	*	*
	<5 years	144	133	0	*	*	*	*
	Never on ART	0	0	0	*	*	*	*
Total HA:		671	611	0	589	680	543	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.3 Distribution of Antiretroviral Treatment Prescribers INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
EAST KOOTENAY	13	30	53	103
KOOTENAY BOUNDARY	18	38	78	141
OKANAGAN	51	333	245	1117
THOMPSON/CARIBOO/SHUSWAP	29	144	152	596
Total:	111	545	528	1957

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	128

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.4 Distribution of Participants by Age & Sex at Birth FRASER Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	0 - 29	28	25	*	29	784	26	<40
	30 - 49	113	96	*	81	700	89	<40
	50 - 64	154	139	*	105	620	127	<40
	65+	71	69	*	48	670	67	<40
	Total HSDA:	366	329	<5	263	675	309	<40
FRASER NORTH	0 - 29	47	44	0	43	670	46	<40
	30 - 49	378	344	0	309	700	319	<40
	50 - 64	359	339	0	237	690	317	<40
	65+	177	172	0	110	615	160	<40
	Total HSDA:	961	899	0	699	680	842	<40
FRASER SOUTH	0 - 29	73	69	*	59	630	66	<40
	30 - 49	362	333	*	248	675	320	<40
	50 - 64	396	367	*	260	651	339	<40
	65+	168	164	*	120	550	158	<40
	Total HSDA:	999	933	<5	687	640	883	<40
Total HA:		2326	2161	<5	1649	660	2034	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	148	138	*	131	680	138	<40
	30 - 49	853	773	*	638	700	728	<40
	50 - 64	909	845	*	602	660	783	<40
	65+	416	405	*	278	590	385	<40
Total HA:		2326	2161	<5	1649	660	2034	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	1756	1652	*	1203	650	1547	<40
Female	570	509	*	446	690	487	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	2161	53	673	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)





4.5 Distribution of Participants by Program Duration FRASER Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
FRASER EAST	10 years or more	228	211	*	*	*	*	*
	5 years or more	58	43	*	*	*	*	*
	<5 years	80	75	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	366	329	<5	263	675	309	<40
FRASER NORTH	10 years or more	602	569	0	*	*	523	<40
	5 years or more	161	146	0	*	*	135	<40
	<5 years	198	184	0	*	*	179	<40
	Never on ART	0	0	0	*	*	5	<40
	Total HSDA:	961	899	0	699	680	842	<40
FRASER SOUTH	10 years or more	572	529	*	379	650	493	<40
	5 years or more	165	147	*	101	680	139	<40
	<5 years	262	257	*	202	615	245	<40
	Never on ART	0	0	*	5	429	6	58
	Total HSDA:	999	933	<5	687	640	883	<40
Total HA:		2326	2161	<5	1649	660	2034	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	1402	1309	*	942	672.5	1208	<40
	5 years or more	384	336	*	256	690	313	<40
	<5 years	540	516	*	439	630	499	<40
	Never on ART	0	0	*	12	525	14	<40
Total HA:		2326	2161	<5	1649	660	2034	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.6 Distribution of Antiretroviral Treatment Prescribers FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
FRASER EAST	32	70	156	562
FRASER NORTH	28	242	267	1661
FRASER SOUTH	44	568	242	2007
Total:	104	880	665	4230

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
FRASER EAST	211
FRASER NORTH	736
FRASER SOUTH	482
Total:	1429

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.7 Distribution of Participants by Age & Sex at Birth VANCOUVER COASTAL Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	0 - 29	12	11	*	12	810	10	<40
	30 - 49	79	70	*	61	740	70	<40
	50 - 64	130	116	*	82	725	113	<40
	65+	98	94	*	79	670	91	<40
	Total HSDA:	319	291	<5	234	710	284	<40
RICHMOND	0 - 29	9	8	*	9	700	8	<40
	30 - 49	64	59	*	56	605	57	<40
	50 - 64	78	71	*	62	650	72	<40
	65+	28	28	*	26	575	26	<40
	Total HSDA:	179	166	<5	153	620	163	<40
VANCOUVER	0 - 29	107	97	*	93	680	94	<40
	30 - 49	1148	1015	*	847	700	1001	<40
	50 - 64	1477	1376	*	1028	610	1328	<40
	65+	756	715	*	482	610	710	<40
	Total HSDA:	3488	3203	9	2450	640	3133	<40
Total HA:		3986	3660	11	2837	650	3580	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	128	116	*	114	690	112	<40
	30 - 49	1291	1144	*	964	700	1128	<40
	50 - 64	1685	1563	*	1172	620	1513	<40
	65+	882	837	*	587	610	827	<40
Total HA:		3986	3660	11	2837	650	3580	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	3495	3214	*	2374	650	3154	<40
Female	491	446	*	463	680	426	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	3660	56	660	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.8 Distribution of Participants by Program Duration VANCOUVER COASTAL Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH SHORE/COAST GARIBALDI	10 years or more	228	207	*	*	*	202	<40
	5 years or more	42	41	*	*	*	38	<40
	<5 years	49	43	*	*	*	44	<40
	Never on ART	0	0	*	*	*	0	N/A
	Total HSDA:	319	291	<5	234	710	284	<40
RICHMOND	10 years or more	99	91	*	78	635	90	<40
	5 years or more	36	32	*	31	640	30	<40
	<5 years	44	43	*	44	610	43	<40
	Never on ART	0	0	*	0	N/A	0	N/A
	Total HSDA:	179	166	<5	153	620	163	<40
VANCOUVER	10 years or more	2444	2274	0	*	*	2222	<40
	5 years or more	537	459	0	*	*	448	<40
	<5 years	507	470	9	*	*	458	<40
	Never on ART	0	0	0	*	*	5	<40
	Total HSDA:	3488	3203	9	2450	640	3133	<40
Total HA:		3986	3660	11	2837	650	3580	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	2771	2572	0	1874	630	2514	<40
	5 years or more	615	532	0	434	740	516	<40
	<5 years	600	556	11	524	650	545	<40
	Never on ART	0	0	0	5	500	5	<40
Total HA:		3986	3660	11	2837	650	3580	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.9 Distribution of Antiretroviral Treatment Prescribers VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH SHORE/COAST GARIBALDI	37	59	204	582
RICHMOND	9	112	50	347
VANCOUVER	209	5423	708	12289
Total:	255	5594	962	13218

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
Total:	54

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.10 Distribution of Participants by Age & Sex at Birth VANCOUVER ISLAND Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	0 - 29	8	5	0	5	810	5	<40
	30 - 49	84	71	0	55	620	60	<40
	50 - 64	145	136	0	69	700	113	<40
	65+	90	85	0	37	480	82	<40
	Total HSDA:	327	297	0	166	600	260	<40
NORTH VANCOUVER ISLAND	0 - 29	5	5	0	*	*	*	*
	30 - 49	28	23	0	*	*	*	*
	50 - 64	55	49	0	*	*	*	*
	65+	34	33	0	*	*	*	*
	Total HSDA:	122	110	0	60	605	94	<40
SOUTH VANCOUVER ISLAND	0 - 29	30	26	*	13	550	23	<40
	30 - 49	201	173	*	66	600	148	<40
	50 - 64	312	291	*	89	630	257	<40
	65+	168	164	*	34	700	159	<40
	Total HSDA:	711	654	<5	202	625	587	<40
Total HA:		1160	1061	<5	428	610	941	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	43	36	*	22	560	32	<40
	30 - 49	313	267	*	138	600	230	<40
	50 - 64	512	476	*	181	640	412	<40
	65+	292	282	*	87	610	267	<40
Total HA:		1160	1061	<5	428	610	941	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	967	884	*	330	600	784	<40
Female	193	177	*	98	670	157	<40
Unknown	0	0	*	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	1061	58	610	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART**: # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4** or **pVL** tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.11 Distribution of Participants by Program Duration VANCOUVER ISLAND Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
CENTRAL VANCOUVER ISLAND	10 years or more	224	205	0	101	590	183	<40
	5 years or more	54	51	0	32	705	39	<40
	<5 years	49	41	0	33	560	38	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	327	297	0	166	600	260	<40
NORTH VANCOUVER ISLAND	10 years or more	93	82	0	40	605	72	<40
	5 years or more	11	11	0	6	655	7	<40
	<5 years	18	17	0	14	635	15	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	122	110	0	60	605	94	<40
SOUTH VANCOUVER ISLAND	10 years or more	433	412	*	*	*	*	*
	5 years or more	135	113	*	*	*	*	*
	<5 years	143	129	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
	Total HSDA:	711	654	<5	202	625	587	<40
Total HA:		1160	1061	<5	428	610	941	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	750	699	*	*	*	*	*
	5 years or more	200	175	*	*	*	*	*
	<5 years	210	187	*	*	*	*	*
	Never on ART	0	0	*	*	*	*	*
Total HA:		1160	1061	<5	428	610	941	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.12 Distribution of Antiretroviral Treatment Prescribers VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
CENTRAL VANCOUVER ISLAND	67	210	215	984
NORTH VANCOUVER ISLAND	32	61	155	367
SOUTH VANCOUVER ISLAND	48	614	241	2088
Total:	147	885	611	3439

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
CENTRAL VANCOUVER ISLAND	91
NORTH VANCOUVER ISLAND	47
SOUTH VANCOUVER ISLAND	126
Total:	264

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.13 Distribution of Participants by Age & Sex at Birth NORTHERN Health Authority (HA)

Health Service Delivery Area	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	45	38	0	43	600	35	<40
NORTH WEST	0 - 29	*	*	0	*	*	*	*
	30 - 49	*	*	0	*	*	*	*
	50 - 64	*	*	0	*	*	*	*
	65+	*	*	0	*	*	*	*
	Total HSDA:	73	64	0	63	600	55	<40
NORTHERN INTERIOR	0 - 29	7	7	0	7	710	7	<40
	30 - 49	66	53	0	59	680	47	<40
	50 - 64	69	67	0	66	505	59	<40
	65+	33	32	0	33	550	28	<40
	Total HSDA:	175	159	0	165	580	141	<40
Total HA:		293	261	0	271	590	231	<40

	Age Group	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	0 - 29	13	12	0	13	600	12	<40
	30 - 49	106	84	0	92	640	76	<40
	50 - 64	123	117	0	116	540	100	<40
	65+	51	48	0	50	550	43	<40
Total HA:		293	261	0	271	590	231	<40

Sex at Birth	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	193	176	0	178	590	154	<40
Female	100	85	0	93	580	77	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total HA:	261	54	610	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
 # **on ART:** # of participants on antiretroviral treatment (ART) in the specified month based on dispensing record
 # **CD4 or pVL tested:** participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/ μ L and pVL in copies/mL)



4.14 Distribution of Participants by Program Duration NORTHERN Health Authority

HSDA	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
NORTH EAST	10 years or more	22	*	0	*	*	*	*
	5 years or more	5	*	0	*	*	*	*
	<5 years	18	*	0	*	*	*	*
	Never on ART	0	*	0	*	*	*	*
	Total HSDA:	45	38	0	43	600	35	<40
NORTH WEST	10 years or more	50	43	0	42	605	36	<40
	5 years or more	8	7	0	7	630	8	<40
	<5 years	15	14	0	14	565	11	<40
	Never on ART	0	0	0	0	N/A	0	N/A
	Total HSDA:	73	64	0	63	600	55	<40
NORTHERN INTERIOR	10 years or more	117	111	0	*	*	102	<40
	5 years or more	33	25	0	*	*	22	<40
	<5 years	25	23	0	*	*	17	<40
	Never on ART	0	0	0	*	*	0	N/A
	Total HSDA:	175	159	0	165	580	141	<40
Total HA:		293	261	0	271	590	231	<40

	Program Duration	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
	10 years or more	189	171	0	*	*	153	<40
	5 years or more	46	35	0	*	*	34	<40
	<5 years	58	55	0	*	*	44	<40
	Never on ART	0	0	0	*	*	0	N/A
Total HA:		293	261	0	271	590	231	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in HIV Treatment Program, not known to be deceased or formally reported as moved out of program

on ART: Participants on antiretroviral treatment (ART) in the specified month based on dispensing record (as above footnote)

Program Duration: years since first antiretroviral treatment dispensing in BC HIV Treatment Program

CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively





4.15 Distribution of Antiretroviral Treatment Prescribers NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers currently prescribing Antiretroviral Treatment	# of Participants currently treated by Prescribers	# of Prescribers ever prescribed Antiretroviral Treatment	# of Participants ever treated by Prescribers
NORTH EAST	1	*	37	50
NORTH WEST	14	*	94	178
NORTHERN INTERIOR	21	*	129	555
Total:	36	224	260	783

HSDA of Participant Residency	# of Participants with Prescriber out of HA/HSDA
NORTH EAST	8
NORTH WEST	29
NORTHERN INTERIOR	26
Total:	63

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Currently prescribing Antiretroviral Treatment: number of prescribers of antiretroviral treatment dispensed in the previous 6 months (based on participant HA/HSDA)

Currently treated: number of participants with antiretroviral treatment dispensed in the previous 6 months by antiretroviral treatment prescribers (based on follow-up prescriber HA/HSDA)

Prescribers ever prescribed Antiretroviral Treatment: for participants residing in HA/HSDA

Participants ever treated by prescribers: where follow-up prescriber is in the HA/HSDA

Participants with Prescriber out of HA/HSDA: participants residing in specified HA/HSDA with follow-up prescriber(s) in another HA/HSDA



4.16 Distribution of Indigenous Participants by Health Service Delivery Area and Sex at Birth

HA	HSDA	# Enrolled	# on ART	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
INTERIOR	EAST KOOTENAY	*	*	0	*	*	*	*
	KOOTENAY BOUNDARY	*	*	0	*	*	*	*
	OKANAGAN	*	*	0	*	*	*	*
	THOMPSON/CARIBOO/SHUSWAP	*	*	0	*	*	*	*
	Total HA:	51	46	0	44	575	36	<40
FRASER	FRASER EAST	30	26	0	23	640	23	<40
	FRASER NORTH	42	38	0	33	451	35	<40
	FRASER SOUTH	60	56	0	41	570	52	<40
	Total HA:	132	120	0	97	558	110	<40
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	25	0	22	775	23	<40
	RICHMOND	5	5	0	5	560	5	<40
	VANCOUVER	363	331	0	337	500	317	<40
	Total HA:	395	361	0	364	515	345	<40
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	45	41	0	26	565	38	<40
	NORTH VANCOUVER ISLAND	16	13	0	9	440	9	<40
	SOUTH VANCOUVER ISLAND	44	38	0	14	595	30	<40
	Total HA:	105	92	0	49	580	77	<40
NORTHERN	NORTH EAST	11	9	0	11	500	8	<40
	NORTH WEST	34	30	0	30	515	24	<40
	NORTHERN INTERIOR	63	56	0	60	490	51	<40
	Total HA:	108	95	0	101	490	83	<40
Total:	791	714	0	655	540	651	<40	

Sex at Birth	# Enrolled	# on Antiretroviral Treatment	# First Starts	# CD4 Tested	Median CD4	# pVL Tested	Median pVL
Male	496	454	0	398	515	411	<40
Female	295	260	0	257	560	240	<40
Unknown	0	0	0	0	N/A	0	N/A

Currently on antiretroviral treatment	# of Participants	Median Age	Median CD4	Median pVL
Total:	714	55	550	<40

* Participant values and corresponding data > 0 and < 5 are suppressed for privacy purposes.

Enrolled: Participants who had enrolled in the HIV Treatment Program, but not known to be deceased or formally reported as moved out of program
on Antiretroviral Treatment: defined as # of Participants being on antiretroviral treatment in the specified month
CD4 or pVL tested: participants tested for CD4 or pVL within the past 12 months and 6 months, respectively (CD4 in cells/μL and pVL in copies/mL)





BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

Funding for the BC Centre for Excellence in HIV/AIDS and HIV Drug Treatment Program provided in-part by:

